Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Proposed combination enhances Pfizer’s position as a leading company in oncology
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
AI-based medical imaging equipment firm Lunit has signed a contract to supply AI-based breast cancer screening solution “Lunit Insight MMG”
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
Subscribe To Our Newsletter & Stay Updated
